{"title":"[Regulatory science research to facilitate the development of cell/tissue-processed products].","authors":"Yoji Sato, Hideki Tsutsumi, Rumi Sawada, Takayoshi Suzuki, Satoshi Yasuda","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Regenerative medicine is regarded as innovative therapy for severe diseases and damages caused by tissue loss and functional impairment. In Japan, regenerative medicine is one of the most important subjects issued by Council for Science and Technology Policy and also referred to in Medical Innovation of New Growth Strategy. Cell/tissue-processed products are living cells, which have been manipulated or processed for the purpose of regenerative medicine, and are extensively developing. Human somatic cells, somatic stem cells, embryonic stem cells, and induced pluripotent stem cells are cell sources used for regenerative medicine. Since we lack in experiences with cell/tissue-processed products, technical development of safety and quality assessment is urgently needed. National Institute of Health Sciences has carried out a mission of Regulatory Science and worked on safety assessment of pharmaceuticals and medical devices and their guideline development. The objective of our study is to develop safety and quality assessment methods for cell/tissue-processed products derived from stem cells, based on recent progresses in life science. We are currently developing methods to evaluate products as follows; a) useful and quantitative tumorigenicity tests to detect contamination of undifferentiated and/or abnormal cells in products, b) quality assessment by gene expression analysis and detection of genetic stability in a manufacturing process, and c) analysis of quality attributes associated with propensity of undifferentiated cells to set acceptable criteria of cell banks. We will be able to provide indicators to control the quality, efficacy and safety of stem cell-processed products and support efficient and economical promotion of the products. Especially, this study would help translate stem cell science into therapeutic products to patients with severe and life-threatening diseases, consequently contributing to administrative policy of Ministry of Health, Labor and Welfare.</p>","PeriodicalId":35462,"journal":{"name":"Bulletin of National Institute of Health Sciences","volume":" 131","pages":"16-9"},"PeriodicalIF":0.0000,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin of National Institute of Health Sciences","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Regenerative medicine is regarded as innovative therapy for severe diseases and damages caused by tissue loss and functional impairment. In Japan, regenerative medicine is one of the most important subjects issued by Council for Science and Technology Policy and also referred to in Medical Innovation of New Growth Strategy. Cell/tissue-processed products are living cells, which have been manipulated or processed for the purpose of regenerative medicine, and are extensively developing. Human somatic cells, somatic stem cells, embryonic stem cells, and induced pluripotent stem cells are cell sources used for regenerative medicine. Since we lack in experiences with cell/tissue-processed products, technical development of safety and quality assessment is urgently needed. National Institute of Health Sciences has carried out a mission of Regulatory Science and worked on safety assessment of pharmaceuticals and medical devices and their guideline development. The objective of our study is to develop safety and quality assessment methods for cell/tissue-processed products derived from stem cells, based on recent progresses in life science. We are currently developing methods to evaluate products as follows; a) useful and quantitative tumorigenicity tests to detect contamination of undifferentiated and/or abnormal cells in products, b) quality assessment by gene expression analysis and detection of genetic stability in a manufacturing process, and c) analysis of quality attributes associated with propensity of undifferentiated cells to set acceptable criteria of cell banks. We will be able to provide indicators to control the quality, efficacy and safety of stem cell-processed products and support efficient and economical promotion of the products. Especially, this study would help translate stem cell science into therapeutic products to patients with severe and life-threatening diseases, consequently contributing to administrative policy of Ministry of Health, Labor and Welfare.
再生医学被认为是治疗由组织丧失和功能损伤引起的严重疾病和损伤的创新疗法。在日本,再生医学是科学技术政策委员会(Council for Science and Technology Policy)发布的重要课题之一,也是新增长战略(New Growth Strategy)中提及的医学创新。细胞/组织加工产品是活细胞,已被操纵或加工为再生医学的目的,并正在广泛发展。人类体细胞、体细胞干细胞、胚胎干细胞和诱导多能干细胞是用于再生医学的细胞来源。由于缺乏细胞/组织加工产品的经验,迫切需要安全质量评估的技术开发。国家卫生科学研究所承担着监管科学的使命,致力于药品和医疗器械的安全评估及其指南的制定。本研究的目的是基于生命科学的最新进展,开发干细胞细胞/组织加工产品的安全性和质量评估方法。我们目前正在开发的产品评估方法如下:A)有用和定量的致瘤性试验,以检测产品中未分化和/或异常细胞的污染,b)通过基因表达分析和制造过程中遗传稳定性检测进行质量评估,以及c)分析与未分化细胞倾向相关的质量属性,以制定细胞库的可接受标准。为控制干细胞加工产品的质量、疗效和安全性提供指标,支持干细胞加工产品的高效、经济推广。特别是,这项研究将有助于将干细胞科学转化为治疗严重和危及生命的疾病的产品,从而有助于厚生劳动省的行政政策。